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A 27-year-old woman had acute panuveitis, associated with bilateral knee pain with morning stiffness,
erythematous papules on the bilateral anterior legs, vertigo, and hearing impairment 4 days after
administration of the third dose of quadrivalent human papillomavirus vaccine (HPV4). The only
abnormal laboratory ﬁnding was an elevated erythrocyte sedimentation rate. Skin biopsy of the local
erythematous papules disclosed septal panniculitis with lymphocytic vasculitis. Complete remission was
achieved with oral and topical steroids for 4 months. There was no recurrence in the following 2 years.
Ophthalmologists and primary-care physicians should be aware of this possible adverse reaction to HPV4.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Human papillomavirus (HPV) is a common sexually transmitted
infection, and certain high-risk HPV types act as carcinogens causing
cervical cancers. Millions of new HPV infections occur annually in
United States, and the related cervical cancer is the second most
common cancer in women [1]. Vaccination with quadrivalent HPV
vaccine (HPV4; Gardasil, Merck & Co., Inc., Whitehouse Station, New
Jersey, USA) has been demonstrated to decrease the incidence of HPV-
associated anogenital diseases and high-grade cervical lesions [2e5].
The Advisory Committee on Immunization Practices recommends
adding HPV vaccine into the adult immunization schedule [6,7].
However, HPV4-related adverse events have been reported, including
autoimmune phenomena such as scleroderma and rheumatoid
arthritis [8]. One case of HPV4-related uveitis has so far been reported
[9].Wereportanothercaseofuveitis followingadministrationofHPV4.
2. Case report
A 27-year-old female resident doctor complained of acutely
painful, inﬂamed eyes with ﬂoaters, which developed 4 days afterlmology, Buddhist Tzu Chi
ualien, Taiwan. Tel.: þ886 3
e).
ddhist Compassion Relief Tzu Chishe received the third dose of HPV4. Concomitant symptoms
included bilateral knee pain with morning stiffness, erythematous
papules on the bilateral anterior legs, vertigo, and hearing impair-
ment. She denied any medication use, recent life changes, or family
history of autoimmune disease. She had no adverse effects after the
previous two doses of HPV4. On examination, she had a visual
acuity of 16/20 in each eye and an intraocular pressure of 6 and
7 mmHg in her right and left eye, respectively. Biomicroscopy
revealed ciliary injection, an anterior chamber reaction with
cells þþþ, keratic precipitates, and snowball aggregates of
inﬂammatory cells in the vitreous. Fundus examination showed
some ﬂame-shaped hemorrhages, and cotton wool patches in the
left eye (Fig. 1A). Leakage from the peripheral retinal vessels was
detected on ﬂuorescein angiography (Fig. 1B). Laboratory exami-
nation revealed an elevated erythrocyte sedimentation rate
(34 mm/h). The complete blood cell count showed no abnormali-
ties. Rapid plasma antigen, Treponema pallidum hemagglutination,
antinuclear antibody, and rheumatic factor were nonreactive. The
human leukocyte antigen B27 was negative. Chest radiography
showed no hilar lymphadenopathy. A skin biopsy of the local
erythematous papules disclosed septal panniculitis with lympho-
cytic vasculitis (Fig. 2). Oral prednisolone 1 mg/kg/d, methotrexate
5 mg weekly, and topical betamethasone 1% every 2 hours for 2
weeks were prescribed. Prednisolone was tapered in 4 months. The
ﬁnal visual acuity was 20/15 in both eyes. There was no recurrence
of uveitis or other symptoms in the following 2 years.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) Fundus examination at presentation (4 days after vaccination) reveals some cotton wool patches with ﬂame-shaped hemorrhages in the left eye. (B) Fluorescein
angiography demonstrates leakage from the peripheral retinal vessels in both eyes.
Fig. 2. Pathological examination of a deep skin biopsy shows septal panniculitis with lymphocytic vasculitis (magniﬁcation 400). (A) The septum of the adipose tissue is inﬁltrated
by mononuclear inﬂammatory cells and lymphoplasma cells. (B) The arteriole shows intimal hyperplasia with vessel-wall mucinosis. Immunohistochemical staining of the
specimen shows many (C) CD3 (þ) cells and (D) CD68 (þ) cells in the septum and vessel walls.
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There are reports of uveitis associated with various vaccines,
including hepatitis B, varicella zoster, meningococcal C conjugated,
and Bacille CalmetteeGuérin (BCG) vaccines [10e12]. HPV4-related
uveitis has been reported only in one case of bilateral ampiginous
choroiditis, which was not associated with other systemic mani-
festations and occurred 3 weeks after HPV4 vaccination [9]. In
contrast, our patient had panuveitis, arthritis, panniculitis, and
some acoustic symptoms. These adverse effects developed 4 days
after vaccination, sooner than that in the previously reported case.
Molecular mimicry and antigenic similarity between proteins
from Mycobacterium tuberculosis and retinal antigens have been
proposed as a potential cause of uveitis elicited by the BCG vaccine
[12]. Computer-assisted analysis showed that HPV type16 E7
oncoprotein had a high, widespread similarity to several human
proteins involved in critical regulatory processes, and different E7
peptide motifs were present in the same human proteins [13].
While sharing the common motifs between viral proteins and
molecules of normal cells might be one cause underlying the scarce
immunogenicity of HPV infections [13], the mimicry between
proteins in HPV4 and human proteins might be the cause under-
lying uveitis or other autoimmune reactions elicited by HPV4.
Although direct histopathological study of the ocular tissue was
not available, the uveitis in our patient was likely some kind of
vasculitis. First, pathological study of the skin biopsy showed
intimal proliferation and vessel-wall hyalinization with many
monocytes/macrophages and lymphocytes, compatible with
lymphocytic vasculitis [14]. Second, the fundus examination
demonstrated some cotton wool patches and hemorrhages,
consistent with destruction and obliteration of small vessels.
Development of an autoimmune reaction in our patient
occurred earlier after vaccination and involved more organs than
the previously reported case. This might be due to an older-than-
recommended age at vaccination, or an existing HPV infection
before vaccination. The suggested age for vaccination is between 9
and 26 years. Vaccination at older ages is not recommended
because of possible existing HPV infection. Administration of HPV4
in a patient with pre-existing HPV infection might rechallenge
certain viral antigens similar to self-proteins and thus cause a more
severe autoimmune reaction. A recent study [5] in patients with
prior infection suggested that natural HPV-infection-elicited anti-
bodies might not provide complete protection against cervical
disease over time, while HPV4 prevented reinfection or reactivationof diseases of the vaccine type. However, vaccine-related adverse
experiences were higher.
In summary, the course in this patient suggested an HPV4-
related uveitis. Molecular mimicry might lead to systemic auto-
immunologic disorders. Ophthalmologists and primary-care
physicians should be aware of this possible adverse reaction,
especially in patients older than the recommended age or with
possible pre-existing HPV infection.
References
[1] Weinstock H, Berman S, Cates Jr W. Sexually transmitted diseases among
American youth: incidence and prevalence estimates, 2000. Perspect Sex
Reprod Health 2004;36:6e10.
[2] FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus
to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915e27.
[3] Ault KA, Future II Study Group. Effect of prophylactic human papillomavirus
L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade
2, grade 3, and adenocarcinoma in situ: a combined analysis of four rando-
mised clinical trials. Lancet 2007;369:1861e8.
[4] Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM,
Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to
prevent anogenital diseases. N Engl J Med 2007;356:1928e43.
[5] Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M,
Wheeler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efﬁcacy
against cervical and anogenital disease in subjects with serological evidence of
prior vaccine type HPV infection. Hum Vaccin 2009;5:696e704.
[6] Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER.
Centers for Disease Control and Prevention (CDC); Advisory Committee on
Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine:
recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR Recomm Rep 2007;56:1e24.
[7] Centers for Disease Control and Prevention (CDC). Recommendations on the
use of quadrivalent human papillomavirus vaccine in malesdAdvisory
Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal
Wkly Rep 2011;60:1705e8.
[8] Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure
safety surveillance for quadrivalent human papillomavirus recombinant
vaccine. JAMA 2009;302:750e7.
[9] Khalifa YM, Monahan PM, Acharya NR. Ampiginous choroiditis following
quadrivalent human papilloma virus vaccine. Br J Ophthalmol 2010;94:137e9.
[10] Yang DS, Hilford DJ, Conrad D. Acute posterior multifocal placoid pigment
epitheliopathy after meningococcal C conjugate vaccine. Clin Experiment
Ophthalmol 2005;33:219e21.
[11] Sedaghat M, Zarei-Ghanavati S, Shokoohi S, Ghasemi A. Panuveitis and dermal
vasculitis following MMR vaccination. East Mediterr Health J 2007;13:470e4.
[12] Garip A, Diedrichs-Möhring M, Thurau SR, Deeg CA, Wildner G. Uveitis in
a patient treated with Bacille-CalmetteeGuérin: possible antigenic mimicry of
mycobacterial and retinal antigens. Ophthalmology 2009;116:2457e62.
[13] Natale C, Giannini T, Lucchese A, Kanduc D. Computer-assisted analysis of
molecular mimicry between human papillomavirus 16 E7 oncoprotein and
human protein sequences. Immunol Cell Biol 2000;78:580e5.
[14] Kossard S. Deﬁning lymphocytic vasculitis. Australas J Dermatol 2000;41:
149e55.
